Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

ls to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit‐risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non‐clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnership for Empatic on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10‐Q filed with the Securities and Exchange Commission August 7, 2013 and its other reports, which are available from the SEC's website (www.sec.gov) and on Orexigen's website
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... , Sept. 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ... all lots of its Mylan-Nitro Spray 0.4 mg/metered dose due ... of the pump component. A missing "dip ... nitroglycerin to the patient. This defect may lead patients to ... are unable to access it. Not receiving nitroglycerin could place ...
(Date:9/19/2014)... 2014 Medical science liaisons (MSLs) play ... opinion leaders (KOLs) who can provide essential insights ... nature of the MSL function, the changing regulatory ... landscape for creating and maintaining KOL and physician ... oversight responsibility for the MSL function is increasingly ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014 ... claims against the board of directors of PDL BioPharma, ... ) concerning whether the board has breached its fiduciary ... On September 16, 2014, the Company disclosed: ... its independent registered accounting firm, Ernst & Young LLP ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: AEN ... system diseases, announced today that it has executed an agreement ... at approximately $2.0725 per share to a new institutional investor ... proceeds. The investor will also receive warrants to purchase approximately ...
... Graymark Healthcare Inc. (NASDAQ: GRMH ), ... and an innovator in comprehensive care for obstructive sleep ... resupply shipments in the first quarter of 2011.  Resupply ... in what is typically the slowest quarter of the ...
Cached Medicine Technology:Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3Graymark Resupply Orders Reach Record Levels in Q1 2011, Up 107% Year-Over-Year 2Graymark Resupply Orders Reach Record Levels in Q1 2011, Up 107% Year-Over-Year 3
(Date:9/20/2014)... York, NY (PRWEB) September 20, 2014 ... Ariana Grande concert tickets . This popular ticket exchange ... savings. , The 2015 schedule of tours is ... music have already announced their plans to hit the road, ... Boca Raton, Fla., announced the “Honeymoon Tour,” which will take ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... Ariana Grande concert tickets. This popular ticket ... added savings. , Ariana Grande is nearing that next step ... is already considered a superstar in the music and entertainment ... who recently released her second straight No. 1 album, will ...
(Date:9/20/2014)... Loma Linda, CA (PRWEB) September 20, 2014 ... Center will receive a $250,000 pediatric cancer research grant ... event at Loma Linda University Children’s Hospital located on ... support the work of Dr. Kimberley Payne, Associate Professor ... Dr. Payne’s work focuses on leukemia in children. ...
(Date:9/20/2014)... September 20, 2014 As testosterone ... in federal court, Bernstein Liebhard LLP notes that ... (FDA) have voted overwhelmingly to recommend that prescription ... be subjected to further study in order to ... published on September 18th by Bloomberg.com, the panel ...
(Date:9/20/2014)... The print component of “Work-Life Balance” is ... Herald, with a circulation of approximately 97,000 copies ... component is distributed nationally through a vast social ... news sites and partner outlets. To explore the ... . , The publication features an exclusive Mediaplanet ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2
... , WASHINGTON, June 4 The U.S. Agency ... and expand children,s immunization programs in developing countries. , ... to global health and the new global health initiative, a ... May. , , The grant was announced by Deputy ...
... Celebrity volunteers who led more than one million people in March for ... March of Dimes raise urgently needed funds for programs that help moms ... had a premature child, I know firsthand the toll that premature birth ... in supporting the March of Dimes," says Sherri Shepherd ...
... , Fruit2O(R) Essentials(TM) Offers Nutritional Benefits and Flavor of Fruit ... 4 From the creators of Fruit2O(R), the original fruit ... - Fruit2O(R) Essentials(TM) - providing nutrients found in two servings ... , , Studies have shown that 80 percent of ...
... , SAN DIEGO, June 4 Last night, the ... Highmark Blue Shield, Keystone Mercy Health Plan, Group Health ... Plan: four health plans with innovative programs designed to ... country. They carry on a tradition among health plans ...
... , LAWRENCE, Mass., June 4 NxStage Medical, Inc. (Nasdaq: ... products, today announced that Jeffrey H. Burbank, Chief Executive Officer, ... on Tuesday, June 9, 2009 at The Four Seasons Hotel ... is scheduled for Tuesday, June 9th at 4:30 p.m. (CST). ...
... protein that could lead to treatment or prevention , THURSDAY, ... that plays a key role in cell death in Huntingdon,s ... loss of intellectual functioning. , The discovery raises hope that ... according to a study in the June 5 issue of ...
Cached Medicine News:Health News:U.S. Contributes $75 Million for Childhood Immunization 2Health News:Celebrities Lead One Million Walkers and Urge Public to Support March for Babies(R) 2Health News:Celebrities Lead One Million Walkers and Urge Public to Support March for Babies(R) 3Health News:Fruit2O(R) Introduces New 'Essentials' Line 2Health News:Fruit2O(R) Introduces New 'Essentials' Line 3Health News:AHIP Foundation Announces 2009 Community Leadership Awards 2Health News:NxStage to Present at the William Blair Growth Stock Conference 2Health News:Discovery Sheds Light on Huntington's Disease 2Health News:Discovery Sheds Light on Huntington's Disease 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: